Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering...
March 27, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer

Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a...
November 19, 2024 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...
October 17, 2024 14:35 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
April 02, 2024 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Share Mean intraocular pressure (IOP) reduction from washed-out baseline was 44.6% at Month 12; all patients had IOP reduction >20% and IOP ≤ 18 mmHg. 100% of patients remained off topical...
December 05, 2023 09:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform

Margot Goodkin, M.D., Ph.D., appointed Chief Medical OfficerBilal Khan, MBA, CEO of New World Medical, appointed to the SpyGlass Board of Directors ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE...
October 31, 2023 07:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform

ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial...
February 03, 2023 11:15 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

ALISO VIEJO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing...
September 29, 2022 15:15 ET | Source: Spyglass Pharma, Inc.

SpyGlass Pharma Presents Compelling 3-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

ALISO VIEJO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, today announced 3-month data from a First-in-Human glaucoma treatment trial...